Clinical

A pair of abstracts presented at this year’s 64th American Society of Hematology Annual Meeting and Exposition bear out the significant transfusion-free rate at 3 years following beti-cell administration and marked improvements in patient-reported outcomes, including the ability to work and be physically active.

A retrospective study found roxadustat to be more effective in improving hemoglobin levels in patients who had with chronic kidney disease (CKD) compared with recombinant human erythropoietin.

Overall survival for patients with combined hepatocellular-cholangiocarcinoma is poor, but those who received adjuvant transarterial chemoembolization (TACE) after surgery had a prolonged recurrence-free survival (RFS).

This new study, which followed patients up to 6 months after functional endoscopic sinus surgery, evaluated results using objective and subjective measures.

Although rare, stiff person syndrome spectrum disorders can significantly affect patient quality of life, and current knowledge gaps warrant further research.

In her final thoughts regarding gastroesophageal cancer, Laura Bobolts, PharmD, BCOP, overviews patient support services and programs.

Laura Bobolts, PharmD, BCOP, shares her perspective surrounding cost-effective analyses surrounding GI and esophageal cancers.

Laura Bobolts, PharmD, BCOP, discusses GI and esophageal cancer treatment pathway decisions.

Expert panelists consider factors affecting treatment adherence for patients with MDD.

Drs Weaver and Chitre illustrate a population health approach strategy for MDD.

A recent meta-analysis found ASXL1 mutations to be independent risk factors for worse overall survival and transformation to acute myeloid leukemia in patients with myelodysplastic syndromes (MDS), as well as worse overall survival in acute myeloid leukemia (AML).

M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, identifies key tools in de-escalating treatment for patients with multiple myeloma.

The top news out of the annual meeting of the American Society of Clinical Oncology (ASCO) highlighted findings in gliobastoma, HER2-low breast cancer, and Hodgkin lymphoma.

The study also showed daily energy intake was inversely correlated with estimated glucose disposal rate (eGDR), a marker for insulin resistance (IR).

Implantable cardioverter defibrillators (ICDs) were found to have a beneficial effect on mortality in patients with chronic kidney disease (CKD).

Jorge Larranaga, MD, discusses the AURORA 2 study and its emphasis on voclosporin.

Belimumab and voclosporin are highlighted as key contributors to the lupus nephritis treatment landscape.

Although the skin condition is common in systemic lupus erythematosus (SLE), it usually is not the initial manifestation.

Jaime Murillo, MD, discusses the impact of diabetes on cardiovascular disease.

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, leads a discussion surrouding early intervention in the management of type 2 diabetes.

Addressing cancer patients' lack of housing or food insecurity affects care outcomes, but how can the Center for Medicare and Medicaid Innovation build this into a reward structure?

Abstracts presented at the annual meeting of the American College of Rheumatology (ACR) show 2 tocilizumab biosimilars were comparable to the reference product.

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA).

Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies.

Cutting the amount of Monthly Enhanced Oncology Services payments and limiting qualifying tumor types will curtail revenue to practices. But after the financial results in the Oncology Care Model, that's by design.

Unlike the Oncology Care Model, the Enhancing Oncology Model will focus on 7 common cancer types, which experts say offers advantages and disadvantages for practices.

The longer follow-up in the primary analysis of TRANSFORM provides confidence in the durability of patient responses to lisocabtagene maraleucel (liso-cel), said Jeremy Abramson, MD, director of the lymphoma program, Massachusetts General Hospital Cancer Center.

Among the conference highlights from the annual meeting of the Academy of Managed Care Pharmacy (AMCP) were an interview on chimeric antigen receptor T-cell therapies and a session on best practices for value-based contracting.

Results from the ALPINE trial were presented Tuesday at a late-breaking session of the 64th American Society of Hematology Annual Meeting and Exposition, held in New Orleans, Louisiana.